Tayup ŞİMŞEK, Selen DOĞAN, Özer BİRGE, Mehmet Sait BAKIR, Hasan Aykut TUNCER, Ceyda KARADAĞ

PET/CT dilemma in para-aortic lymph node assessment in locally advanced cervical cancer?

Objective: We aimed to discuss the relationship between the maximum standardized uptake value (SUVmax), which is the degree of involvement obtained in the radiopharmaceutical 18-Fluor-labeled glucose-utilized positron emission tomography-computed tomography (PET-CT), which is widely used in locally advanced cervical cancer, and para-aortic lymph node positivity as a result of histopathology in the light of the literature. Material and Methods: The pre-operative PET-CT results of 66 patients who had been examined and treated for locally advanced (Stage IB3-IVA) cervical cancer between 2015 and 2020 were retrospectively examined and the relationship between the SUVmax values and para-aortic lymph node positivity in the histopathology results was evaluated. Patients with SUVmax 4≤ in PET-CT were accepted to have paraaortic lymph node involvement. In terms of para-aortic lymph involvement, a cross tabulation was created with PET-CT results and the final pathology, which is the gold standard, and the sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV) were calculated. Results: The mean age of 66 patients included in our study was 48.2±13.2 years. The majority of our patients were at stage 1B3 (36.4%), while eight were at stage 3C2P. While para-aortic evaluation was performed through the laparoscopic method in 36 (54.5%) patients, it was performed by laparotomy in the remaining 30 (45.5%) patients. When the complaints of the patients were assessed, it was seen that the highest rate was that of post-coital bleeding in 32 patients (48.5%) and pelvic pain was observed in two patients (3%). The mean body mass index (BMI) was 22.69±4.14 and the squamous type was the most common in 44 patients (66.7%) in terms of histopathological typing. When we evaluated the results of 66 patients, the prevalence rate was around 12% and when we compared the SUVmax uptake rates found in PET-CT, which we used as a new diagnostic test with the pathology results, which is our gold standard test, the sensitivity and specificity rates were 50% and 48%, respectively. The PPV, the NPV, and accuracy were calculated as 11.7%, 87.5%, and 48.8%, respectively. Conclusion: Considering the high risk of para-aortic lymph node metastasis in locally advanced cervical cancer through assessment of the high SUVmax values in PETCT, it is necessary to confirm the status of the para-aortic lymph node with minimally invasive surgery in the foreground by experienced surgeons.

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12–9.
3. Ries LA, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007.
4. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018;143 Suppl 2:22–36.
5. Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynecol Obstet 2019;145(1):129–35.
6. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology. Int J Gynaecol Obstet 2000;70(2):209–62.
7. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105(2):103–4.
8. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105(2):107–8.
9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.
10. Singh N, Arif S. Histopathologic parameters of prognosis in cervical cancer-a review. Int J Gynecol Cancer 2004;14(5):741–50.
11. Brownell GL, Sweet WH. Localization of brain tumors with positron emitters. Nucleonics 1953;11(11):40–5.
12. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, et al. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: A prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 2011;117(9):1928–34.
13. Leblanc E, Gauthier H, Querleu D, Ferron G, Zerdoud S, Morice P, et al. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma. Ann Surg Oncol 2011;18(8):2302–9.
14. Uzan C, Souadka A, Gouy S, Debaere T, Duclos J, Lumbroso J, et al. Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advancedstage cervical cancer and negative PET-CT imaging in the para-aortic area. Oncologist 2011;16(7):1021–7.
15. Wrenn FR Jr., Good ML, Handler P. The use of positron-emitting radioisotopes for the localization of brain tumors. Science 1951;113(2940):525– 7.
16. Pacák J, Cerny M. History of the first synthesis of 2-deoxy-2-fluoro-dglucose the unlabeled forerunner of 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imag Biol 2002;4(5):352–4.
17. Bhatla N, Berek JS, Fredes MC, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145(1):129–35.
18. Parker K, Gallop-Evans E, Hanna L, Adams M. Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: Results from a single institution. Int J Radiat Oncol Biol Phys 2009;74(1):140–6.
19. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001;19(17):3745–9.
20. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005;97(1):183–91.
21. Gold MA, Tian C, Whitney CW, Rose PG, Lanciano R. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: A gynecologic oncology group study. Cancer 2008;112(9):1954–63.
22. Marnitz-Schulze S, Tsunoda A, Martus P, Vieira MV, Affonso R, Nunes JS, et al. UTERUS-11 STUDY: A randomized clinical trial on surgical staging versus ct-staging prior to primary chemoradiation in patients with FIGO2009 stages IIB-IVA cervical cancer. Int J Gynecol Cancer 2019;29(3):A15.